Data compiled by Redley Lamar · ChainSifter Intelligence
8Suppliers
5Customers
1Debt Items
20Related Chains
Source-Backed Evidence Depth
Cyclerion Therapeutics, Inc. (CYCN) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
23Total relationships
5Distinct source URLs
14High confidence
0.846Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Cyclerion Therapeutics, Inc. Suppliers
Ticker
Name
Confidence
Evidence
MEDSTEER-SAS
MEDSTEER-SAS
90%
Under the terms of the Collaboration Agreement, the Company will pay to Medsteer a nominal upfront payment, a payment upon exercise of the Option, and Medsteer will be eligible to receive up to $3.7 …
TISENTO-THERAPEUTICS-HOLDINGS-INC
TISENTO-THERAPEUTICS-HOLDINGS-INC
90%
the shares of common stock of Tisento Therapeutics Holdings, Inc. that were acquired by Cyclerion pursuant to that certain Asset Purchase Agreement
rovides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity for both drugs and biologics, and also unexpired Orange Book listed p…
Reciprocal relationship from JNJ graph: Reciprocal relationship from CYCN graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from CYCN graph: rovides for the attachment of an addi…
rovides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity for both drugs and biologics, and also unexpired Orange Book listed p…
Reciprocal relationship from LLY graph: Reciprocal relationship from CYCN graph: rovides for the attachment of an additional six months of marketing protection to the term of any existing regulatory …
rovides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity for both drugs and biologics, and also unexpired Orange Book listed p…
Reciprocal relationship from ORANY graph: Reciprocal relationship from CYCN graph: rovides for the attachment of an additional six months of marketing protection to the term of any existing regulator…
Cyclerion Therapeutics, Inc. Customers
Ticker
Name
Confidence
Evidence
AKEBIA-THERAPEUTICS-INC
AKEBIA-THERAPEUTICS-INC
92%
Cyclerion’s right to receive payments under that License Agreement, dated June 3, 2021, between Cyclerion and Akebia Therapeutics, Inc.
OPTIONEE
OPTIONEE
90%
On July 22, 2024, we entered into the Option Agreement with the Optionee, which the Optionee had the Option to enter into an exclusive license to olinciguat for human therapeutics, subject to certain…
Reciprocal relationship from IRWD graph: Reciprocal relationship from CYCN graph: ted of the following (in thousands): March 31, December 31, 2026 2025 Professional fees $ 984 $ 143 Employee compensa…
ted of the following (in thousands): March 31, December 31, 2026 2025 Professional fees $ 984 $ 143 Employee compensation 21 13 Other 104 38 Accrued expenses and other current liabilities $ 1,109 $ 1…
KORSANA-BIOSCIENCES-INC
KORSANA-BIOSCIENCES-INC
62%
ted of the following (in thousands): March 31, December 31, 2026 2025 Professional fees $ 984 $ 143 Employee compensation 21 13 Other 104 38 Accrued expenses and other current liabilities $ 1,109 $ 1…
Cyclerion Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
CYCN-DEBT
Debt stack $3.5M
90%
Market cache reports total debt of $3.5M.
Cyclerion Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Cyclerion Therapeutics, Inc..
Cyclerion Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
CYCN-OWNER-VANGUARD-GROUP-INC
Vanguard Group Inc
95%
13F/ownership overlay lists Vanguard Group Inc; shares held 23,490; ownership 0.60%; value $36,409; as of 2025-12-31.
CYCN-OWNER-GEODE-CAPITAL-MANAGEMENT-LLC
Geode Capital Management, LLC
95%
13F/ownership overlay lists Geode Capital Management, LLC; shares held 43,302; ownership 1.10%; value $67,118; as of 2025-12-31.
CYCN-OWNER-TWO-SIGMA-INVESTMENTS-LP
Two Sigma Investments, LP
95%
13F/ownership overlay lists Two Sigma Investments, LP; shares held 41,555; ownership 1.06%; value $64,410; as of 2025-12-31.
CYCN-OWNER-XTX-TOPCO-LTD
Xtx Topco Ltd
95%
13F/ownership overlay lists Xtx Topco Ltd; shares held 10,027; ownership 0.26%; value $15,541; as of 2025-12-31.
CYCN-OWNER-BLACKROCK-INC
Blackrock Inc.
95%
13F/ownership overlay lists Blackrock Inc.; shares held 16,797; ownership 0.43%; value $26,035; as of 2025-12-31.
CYCN-OWNER-FMR-LLC
FMR, LLC
95%
13F/ownership overlay lists FMR, LLC; shares held 4,740; ownership 0.12%; value $7,346; as of 2025-12-31.
CYCN-OWNER-SIREN-L-L-C
Siren, L.L.C.
95%
13F/ownership overlay lists Siren, L.L.C.; shares held 115,603; ownership 2.95%; value $179,184; as of 2025-12-31.
CYCN-OWNER-CITIGROUP-INC
Citigroup Inc.
95%
13F/ownership overlay lists Citigroup Inc.; shares held 8,204; ownership 0.21%; value $12,716; as of 2025-12-31.
CYCN-OWNER-TOWER-RESEARCH-CAPITAL-LLC-TRC
Tower Research Capital LLC (TRC)
95%
13F/ownership overlay lists Tower Research Capital LLC (TRC); shares held 3,154; ownership 0.08%; value $4,888; as of 2025-12-31.
Cyclerion Therapeutics, Inc. Extended Supply Chain Network
